FISIOPATOLOGÍA Y FARMACOLOGÍA
Escuela de doctorado
Universidad de Navarra
Pamplona, EspañaPublicaciones en colaboración con investigadores/as de Universidad de Navarra (46)
2024
-
New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study
Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5
2023
-
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Nature Reviews Gastroenterology and Hepatology, Vol. 20, Núm. 7, pp. 462-480
-
Identification and experimental validation of druggable epigenetic targets in hepatoblastoma
Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005
-
Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis
Cells, Vol. 12, Núm. 16
-
Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma
Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108
-
Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)
Bone Marrow Transplantation
-
Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution
eLife, Vol. 12
2022
-
Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia
Hepatology, Vol. 76, Núm. 5, pp. 1259-1274
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
-
Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions
Gut, Vol. 71, Núm. 8, pp. 1669-1683
-
Impact of alternative splicing variants on liver cancer biology
Cancers, Vol. 14, Núm. 1
-
New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming
Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1
-
Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome
Frontiers in Immunology, Vol. 13
-
RICORS2040: The need for collaborative research in chronic kidney disease
Clinical Kidney Journal, Vol. 15, Núm. 3, pp. 372-387
-
TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation
Journal of Hepatology, Vol. 77, Núm. 4, pp. 991-1004
-
Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models
Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190
-
The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes
Nature Communications, Vol. 13, Núm. 1
2021
-
Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)
British Journal of Cancer
-
Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma
Hepatology, Vol. 73, Núm. 6, pp. 2380-2396
-
Gene supplementation of CYP27A1 in the liver restores bile acid metabolism in a mouse model of cerebrotendinous xanthomatosis
Molecular Therapy - Methods and Clinical Development, Vol. 22, pp. 210-221